Status:
Ready to upload
Record number:
1646
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
Unusual
Alerting signals, symptoms, evidence of occurrence:
There is a delayed serologic transfusion reaction (DSTR) when, after a transfusion, there is demonstration of clinically significant antibodies against red blood cells which were previously absent (as far as is known) and when there are no clinical or laboratory features of hemolysis. This term is synonymous with alloimmunization. Twenty years of monocyte monolayer (MMA) data were retrospectively analyzed by correlating MMA results from 46 patients with unusual antibodies who had RBC Survival study results and/or laboratory and clinical signs of hemolytic transfusion reactions when incompatible blood was transfused. Antibodies included: Anti-U, anti-Go(a), anti-Rh29, anti-In(b), anti-Lu(a), anti-Lu(b), anti-Lu(3), anti-Lu(8), anti-Lu(12), anti-Ku, anti-K19, anti-Kp(b), anti-Js(b), anti-Jk3, anti-JMH, anti-Di(a), anti-Di(b), anti-Wr(a), anti-Yt(a), anti-Yt(b), anti-Do(a), anti-Do(b), anti-Gy(a), anti-Hy, anti-Jo(a), anti-Co(a), anti-Co(b), anti Es(a), anti-Ge, anti-Ok(a), anti-P, anti-Tj(a), anti-P+P(1)+P(k), anti-GIL, anti-PEL, anti-AnWj, anti-ABTI, anti-At(a), anti-Jr(a), anti-Lan, anti-Vel, anti-I, anti-H, anti-LKE, anti-Ch, anti-Sc1, anti-Yk(a), anti-Kn/McC, anti-Xg(a).
Demonstration of imputability or root cause:
Patients who had been previously identified as having signs of hemolytic transfusion reactions were studied by MMA. No patients with MMA results less than or equal to 5 percent had clinical signs of a reaction; one-third of patients with MMA results 5.1 to 20 percent versus two thirds with results greater than 20 percent had clinical signs of a hemolytic transfusion reactions after transfusion of incompatible blood.
Groups audience:
Keywords:
References:
Suggest new keywords:
Anti-U, anti-Go(a), anti-Rh29, anti-In(b), anti-Lu(a), anti-Lu(b), anti-Lu(3), anti-Lu8, anti-Lu12, anti-Ku, anti-K19, anti-Kp(b), anti-Js(b), anti-Jk3, anti-JMH, anti-Di(a), anti-Di(b), anti-Wr(a), anti-Yt(a), anti-Yt(b), anti-Do(a), anti-Do(b),
anti-Gy(a), anti-Hy, anti-Jo(a), anti-Co(a), anti-Co(b), anti Es(a), anti-Ge, anti-Ok(a), anti-P, anti-Tj(a), anti-P+P(1)+P(k), anti-GIL, anti-PEL, anti-AnWj,
anti-ABTI, anti-At(a), andti-Jr(a), anti-Lan, anti-Vel, anti-I, anti-H, anti-LKE, ant-Ch, anti-Sc1, anti-Yk(a), anti-Kn/McC, anti-Xg(a), MMA, monocyte monolayer
Reference attachment:
Suggest references:
- Arndt PA, Garratty G. (2004). A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 44:1273-81
- Poole J, Daniels G. (2007). Blood group antibodies and their significance in transfusion medicine. Transfus Med Rev 21:58-71
Expert comments for publication:
Most unusual alloantibodies are predicted to cause shortened RBC survival, but transfusion of incompatible blood may not result in any clinical or laboratory signs of an hemolytic transfusion reaction.